Project Grant R01AI169864
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $222,750.00 to the University of Alabama at Birmingham (UAB) to explore the novel functions of the Fc gamma binding protein (FcGBP) in the colon mucus layer and its effects on the gut microbiota. The project aims to determine how FcGBP contributes to the glycosylation and sialylation of the colon mucus...
- This Project Grant award of $3,022,197.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, will fund a study on the role of regulatory T (Treg) cells and the IL-27 cytokine in immune regulation and inflammatory bowel disease. The research team at the University of California, San Diego will employ molecular, biochemical, and immunological approaches to examine the mechanisms driving the expression of...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $252,152 to the Benaroya Research Institute at Virginia Mason to characterize the T cells specific for the autoantigen integrin αvβ6 in patients with ulcerative colitis. The researchers will adapt the Activation Induced Marker (AIM) assay to analyze T cells from the mesenteric lymph nodes and colonic mucosa of...
- This Project Grant award was provided by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The $202,245 award supports research at Pennsylvania State University to elucidate the molecular basis for intestinal homeostasis and its dysregulation in inflammatory bowel diseases (IBD). The research aims to investigate the role of the aryl hydrocarbon receptor (AhR) in regulating intestinal...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $807,799 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to the University of Chicago. The grant, which runs from Jul 15, 2025 to Jun 30, 2030, supports research to investigate the role of a specialized subset of regulatory T cells in controlling self-reactive B cells and the production of autoantibodies. The research aims to identify these B cell-dependent...
- This $108,273 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), supports research to understand the role of mucosal immunity in protecting against SARS-CoV-2 infection and transmission. The central hypothesis is that respiratory IgA antibodies provide neutralization and protection against heterologous infection, facilitated by an interaction between macrophages, CD4 T...
- The University of Pittsburgh was awarded a $379,609 Project Grant by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to investigate how the immune system establishes homeostasis with commensal microbes. The research aims to understand the mechanisms through which B cells balance the need for a diverse repertoire with maintaining self-tolerance, including the potential role of anergized B cells in this process. The award period is...
- This federal Project Grant award of $705,557 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to better understand the coordination of innate and cellular mucosal immunity in SARS-CoV-2 clearance. The primary objectives are to determine the contribution of monocytes in promoting T cell responses and viral control within the respiratory tract, and to define the effector mechanisms of...
- This $556,843 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to advance the understanding of the extrafollicular (EF) B cell response and its role in immunity. The project aims to investigate how the EF response, which produces rapid expansion and differentiation of plasma cells, differs from the more well-studied germinal center (GC) response. Key focus...
- The University of Illinois received a $582,350 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on "Microbiota-Mediated Colonization Resistance to Acinetobacter Baumannii." The research aims to identify key gut resident microbes that can synergize with a complex microbiota to prevent colonization by the multidrug-resistant pathogen Acinetobacter...
This $567,962 project grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases will fund research at the University of Alabama at Birmingham from March 2022 to February 2027 under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant will support research into the coordination of innate and adaptive immunity in intestinal barrier defense. Specifically, the grantee will define the mechanisms by which innate and adaptive immune cells specialize for distinct interleukin-22-dependent actions on different subsets of colonic epithelial cells. This includes investigating the specialized roles of interleukin-22-producing innate immune cells like group 3 innate lymphoid cells and T cells in protecting surface colonic epithelium and colonic crypts from bacterial invasion. Insights gained from this work have the potential to reveal new understandings of immune cell specialization in intestinal host defense and mechanisms controlling intestinal inflammation in conditions like inflammatory bowel disease and colorectal cancer.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $568.0k | 2/28/22 |